University of Central Florida Research Foundation, Inc. (USA)
New Jersey Institute of Technology (USA)
Inventeur(s)
Guido-Sanz, Francisco
Anderson, Mindi
Diaz, Desiree
Talbert, Steven
Daher, Salam
Musa, Dahlia
Abrégé
A method of skin anomaly assessment, measurement, and monitoring is disclosed. The three-dimensional topology of a skin anomaly is digitally scanned, and a three-dimensional model of the skin anomaly is computationally constructed. From the three-dimensional model, length, width, depth, perimeter, and surface area measurements of the skin anomaly are derived. This information may be quantified by volume surface area, and/or distance along the surface of the anomaly, and measured against models of anticipated healing for medical monitoring and training.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
G16H 80/00 - TIC spécialement adaptées pour faciliter la communication entre les professionnels de la santé ou les patients, p. ex. pour le diagnostic collaboratif, la thérapie collaborative ou la surveillance collaborative de l’état de santé
A lipid nanoparticle including: an ionizable cationic lipid compound including a reaction product of an amino alcohol and one or more lipid acids having from 4 to 26 carbons; one or more lipid components selected from a helper neutral lipid, a PEG-modified lipid, a phospholipid, and cholesterol; and a nucleic acid agent, the nucleic acid agent encoding an N-terminal domain of gasdermin. A lipid nanoparticle including: an ionizable cationic lipid compound having a structure of Formula (I); one or more lipid components selected from a helper neutral lipid, a PEG-modified lipid, a phospholipid, and cholesterol; and a single-agent mRNA, the single-agent mRNA encoding an N-terminal domain of gasdermin and including a polynucleotide sequence having at least 90% sequence identity to SEQ ID NO. 1. A method of treating a tumor, the method comprising administering a pharmaceutical composition to a subject in need thereof, the pharmaceutical composition comprising the lipid nanoparticle.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
3.
Method of using binary coating agents in powder coating to achieve enhanced properties of the coated powder and its blends having cohesive powders
A method of employing a mixture of two different types of silica as a binary dry coating material to benefit properties of fine milled pharmaceuticals, such as ibuprofen, milled to the mean particle size of ˜10 μm or smaller. Synergistic effects of reduction in agglomerate size, and improved surface wettability was found by employing a mixture of two different types of silica as the dry coating material in specific ratios. The silica used up to weight percent to 2.31 wt % of a minority component, typically an API or excipient. The silica amount in the entire blend was less than 0.1 wt %. The surface coverage of API was optimized to 50%. Properties were increased when surface coverage by binary coating agents was controlled so that no excess coating agent was available to form agglomerates on the surface.
A computing device includes a processor and a storage device coupled to the processor. The storage device stores instructions to cause the processor to perform acts to provide a circuit performance modeling. The acts include identifying and extracting paths of an electric circuit between a plurality of designated components that represent the electric circuit; converting at least one of the extracted paths to a path embedding comprising a vector of a fixed length; and predicting, by a circuit representation-learning model, characteristics of the designated components that represent the electric circuit based on an input of circuit parameters of the electric circuit.
G06N 3/0442 - Réseaux récurrents, p. ex. réseaux de Hopfield caractérisés par la présence de mémoire ou de portes, p. ex. mémoire longue à court terme [LSTM] ou unités récurrentes à porte [GRU]
G06N 3/084 - Rétropropagation, p. ex. suivant l’algorithme du gradient
A method for absolute quantification of nitrosamines without using standards is disclosed. The method involves reducing nitrosamines to hydrazines and coulometric mass spectrometric (CMS) quantitation is then applied to quantify the hydrazines, thus quantifying their precursor nitrosamines, as the reduction yields can be measured by mass spectrometry (MS).
B01D 15/08 - Adsorption sélective, p. ex. chromatographie
G01N 27/27 - Association de plusieurs systèmes ou cellules de mesure, chacun mesurant un paramètre différent, dans laquelle les résultats des mesures peuvent être, soit utilisès indépendamment, les systèmes ou les cellules étant physiquement associés, soit combinés pour produire une valeur représentative d'un autre paramètre
The disclosure relates to a method for identification via channels in a system having a plurality of data processing devices. The method comprises selecting, in a first data processing device, an identifier indicative of a target second data processing device of a plurality of second data processing devices; determining, in the first data processing device, an outer codeword from the identifier using an outer code comprising a first outer code and a second outer code; determining, in the first data processing device, an optical orthogonal codeword from the outer codeword using an optical orthogonal code; determining, in the first data processing device; a randomly selected codeword from the optical orthogonal codeword using an error correction code; and emitting the selected codeword from the first data processing device via a channel. Further, a computer program product and a system for identification via channels are provided.
H04L 27/26 - Systèmes utilisant des codes à fréquences multiples
H03M 13/15 - Codes cycliques, c.-à-d. décalages cycliques de mots de code produisant d'autres mots de code, p. ex. codes définis par un générateur polynomial, codes de Bose-Chaudhuri-Hocquenghen [BCH]
H04L 1/00 - Dispositions pour détecter ou empêcher les erreurs dans l'information reçue
7.
Non-Volatile Processing-In-Sensor Accelerator For Imaging Systems
Board of Regents of the University of Nebraska (USA)
Inventeur(s)
Angizi, Shaahin
Roohi, Arman
Abrégé
Disclosed is a Processing-In-Sensor Accelerator (PISA) that provides a flexible, energy-efficient, and high-performance solution for real-time and smart image processing in AI devices. PISA implements a coarse-grained convolution operation in Binarized-Weight Neural Networks (BWNNs) leveraging a novel compute-pixel with non-volatile weight storage at the sensor side. This reduces power consumption of data conversion and transmission to an off-chip processor. A bit-wise near-sensor in-memory computing unit processes the remaining network layers. Once the object is detected, PISA switches to typical sensing mode to capture the image for a fine-grained convolution using only a near-sensor processing unit. The circuit-to-application co-simulation results on a BWNN acceleration demonstrate minor accuracy degradation on various image datasets in coarse-grained evaluation compared to baseline BWNN models. PISA achieves a frame rate of 1000 and efficiency of 1.74 TOp/s/W. PISA reduces data conversion and transmission energy by at least 84% compared to a baseline.
H04N 23/65 - Commande du fonctionnement de la caméra en fonction de l'alimentation électrique
G06V 10/75 - Organisation de procédés de l’appariement, p. ex. comparaisons simultanées ou séquentielles des caractéristiques d’images ou de vidéosApproches-approximative-fine, p. ex. approches multi-échellesAppariement de motifs d’image ou de vidéoMesures de proximité dans les espaces de caractéristiques utilisant l’analyse de contexteSélection des dictionnaires
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G16Y 20/10 - Information détectée ou collectée par les objets relative à l’environnement, p. ex. la température relative à l’emplacement
G16Y 40/35 - Gestion des objets, c.-à-d. commande selon une stratégie ou dans le but d'atteindre des objectifs déterminés
H04N 23/61 - Commande des caméras ou des modules de caméras en fonction des objets reconnus
H04N 23/667 - Changement de mode de fonctionnement de la caméra, p. ex. entre les modes photo et vidéo, sport et normal ou haute et basse résolutions
H04N 25/42 - Extraction de données de pixels provenant d'un capteur d'images en agissant sur les circuits de balayage, p. ex. en modifiant le nombre de pixels ayant été échantillonnés ou à échantillonner en commutant entre différents modes de fonctionnement utilisant des résolutions ou des formats d'images différents, p. ex. entre un mode d'images fixes et un mode d'images vidéo ou entre un mode entrelacé et un mode non entrelacé
H04N 25/709 - Circuits de commande de l'alimentation électrique
8.
GENE DELIVERY FOR PREVENTION AND TREATMENT OF BALDNESS
Ionizable cationic lipid compounds have an amine moiety from amino alcohols and a lipid moiety from a lipid synthesized via esterification. The ionizable cationic lipid compounds which comprise an amino alcohol mediated ionizable cationic lipid compound are useful for in vivo or in vitro delivery of one or more nucleic acid agents including DNA, siRNA, a microRNA, an mRNA, a RNAi, and a plasmid.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
Disclosed is a drone-assisted and non-drone assisted NLoS-FSOC network and method for high-speed communications in disaster-struck areas or where there is little or no communications. NLoS-FSOC uses a diffuse reflector that is in LoS of a transmitter and receiver for establishing a broadcast optical channel. NLoS-FSOC establishes uplink and downlink transmissions. The present disclosure services at least 130% more stations and provides at least 100% more aggregated downlink data rates than drone-assisted than RF-based schemes. It also consumes 116 times less energy compared to RF-based schemes by using high-bandwidth optical signals and coherent light of laser light in NLoS-FSOC, optical broadcast channel use, and drone or non-drone front-haul diffuse reflection placement. The present disclosure is used autonomously or in combination with other systems such as RF schemes for a more robust solution to RF schemes alone.
H04B 10/118 - Dispositions spécifiques à la transmission en espace libre, c.-à-d. dans l’air ou le vide spécialement adaptées aux communications par satellite
For example, a method includes collecting orientation data from a mobile device as a user of the mobile device moves within an indoor space, generating orientation estimates for the mobile device from the orientation data, generating distance estimates representing distances of the mobile device to a wireless access point in the indoor space, storing the orientation estimates and the distance estimates together as a series of data blocks, constructing a plurality of trajectory segments from the orientation estimates, identifying identifiers for a last number of trajectory segments, using data blocks corresponding to the last number of trajectory segments, and identifying a predicted place within the indoor space to which the user is expected to go by using the identifiers to traverse a prediction tree, where branches of the prediction tree that are associated with the identifiers define a path that ends at a leaf node corresponding to the predicted place.
A module for gas and/or vapor removal from a fluid stream is provided. The module includes at least one hollow fiber membrane including a first end and an opposing second end. The hollow fiber membrane includes a fiber wall defining an interior bore extending from the first end to the opposing second end and defining a passage for fluid flow through the hollow fiber membrane. The module includes a bed of metal organic framework (MOF) integrated into membrane pores of the fiber wall of the at least one hollow fiber membrane, into the hollow fiber membrane bore, and/or outside of the at least one hollow fiber membrane in an extracapillary space.
B01D 15/10 - Adsorption sélective, p. ex. chromatographie caractérisée par des caractéristiques de structure ou de fonctionnement
B01D 53/04 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p. ex. chromatographie préparatoire en phase gazeuse avec adsorbants fixes
B01D 53/22 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par diffusion
B01D 63/04 - Modules à fibres creuses comprenant plusieurs ensembles à fibres creuses
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétésProcédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
A resistive random access memory (RRAM) device is provided, and includes a top electrode layer, a bottom electrode layer, and an insulating layer positioned between the top electrode layer and the bottom electrode layer. The insulating layer includes a SiNx layer.
H10N 70/00 - Dispositifs à l’état solide n’ayant pas de barrières de potentiel, spécialement adaptés au redressement, à l'amplification, à la production d'oscillations ou à la commutation
H10B 63/00 - Dispositifs de mémoire par changement de résistance, p. ex. dispositifs RAM résistifs [ReRAM]
A method, system, and computer program product for circuit design automation. The method identifies a set of circuit components for a proposed circuit design. A subset of circuit components is selected to generate an initial topology for the proposed circuit design. A set of subsequent topologies are iteratively generated by a heuristic search algorithm based on the subset of circuit components and the initial topology. A set of valid topologies of the set of subsequent topologies are determined by a circuit simulator based on the subset of circuit components and a set of connections within the set of subsequent topologies. The method generates the proposed circuit design from the set of valid topologies.
G06F 30/398 - Vérification ou optimisation de la conception, p. ex. par vérification des règles de conception [DRC], vérification de correspondance entre géométrie et schéma [LVS] ou par les méthodes à éléments finis [MEF]
14.
System and Method for Quantification and Feedback of Eye Deviations
Disclosed is a system, method, and apparatus for quantification and feedback of eye deviations during normal viewing conditions. A sensory biofeedback system serves to emit a sensory cue such as a tone or vibration when a certain threshold of eye deviation has been exceeded. The biofeedback system allows objective monitoring of the accuracy of eye alignment that can be used outside of a clinical setting or inside a clinical setting.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 3/00 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux
A61B 3/08 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure subjective, c.-à-d. appareils de d’examen nécessitant la participation active du patient pour examen de vision binoculaire ou stéréoscopique, p. ex. pour le contrôle du strabisme
A61B 3/113 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
15.
Addressable Microfluidics Systems and Methods for In Vivo Applications
A microfluidic device capable of performing nondisruptive fluid manipulations in a living host is provided. The microfluidic device may include a combinatorial multiplexer for better scaling of multiple time points and biological signal measurements. The collected samples may be transported, stored and analyzed ex vivo for analytical ease and flexibility, e.g., by a sample analysis assay chip. The microfluidics device may include structure for maintaining fluid equilibrium within the host during the sampling to avoid damage to the host or to the implant.
G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
Optically computed phase imaging systems and methods are provided. An example system includes an interferometer configured to output 3D spatial-spectral data of a sample including an interferometric signal and an optical computation assembly having a spatial light modulator configured to modulate the 3D spatial-spectral data with a modulation pattern. The modulation pattern modulates the interferometric signal along a spectral dimension to select a depth to obtain a sample signal at the selected depth and modulates the interferometric signal along a first spatial dimension to create a waveform to facilitate phase extraction. The system further includes a detector configured to detect 2D spatial data of the sample. The system further includes a processor coupled to a memory, the processor configured to process the 2D spatial data to extract phase information of the sample.
Ionizable cationic lipid compounds have an amine moiety from amino alcohols and a lipid moiety from a lipid synthesized via esterification. The ionizable cationic lipid compounds which comprise an amino alcohol mediated ionizable cationic lipid compound are useful for in vivo or in vitro delivery of one or more nucleic acid agents including DNA, siRNA, a microRNA, an mRNA, a RNAi, and a plasmid.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
18.
Powder blend processability improvements through minimal amounts of synergistically selected surface coating agents
High (greater than 30%) and/or low (less than 10%) loaded multiple API powdered/nanoparticle were tabulated with increased flowability and physical properties. Properties include blend flowability and uniformity, bulk packing density, compactability, tensile strength, and dissolution. Blending is done through solventless dry mechanical coating of at least one minority API component defined as the API component with the least weight per volume surface coated with nano-sized powders in lesser amounts by wt % of the blend, and preferably less than 10% dry coated of the minority API. An excipient may be dry coated in the lesser amount wherein the excipient is a minority component. Both minority excipient and minority API may be dry coated. Using dry coating instead of dry granulation and/or wet granulation techniques in producing tablets saves manufacturing steps, costs, and produces higher quality tablets with surprisingly higher properties than expected for low flowability solid powdered ingredients.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites
Ionizable cationic lipid compounds have an amine moiety from amino alcohols and a lipid moiety from a lipid synthesized via esterification. The ionizable cationic lipid compounds which comprise an amino alcohol mediated ionizable cationic lipid compound are useful for in vivo or in vitro delivery of one or more nucleic acid agents including DNA, siRNA, a microRNA, an mRNA, a RNAi, and a plasmid.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
C12P 17/12 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'azote comme unique hétéro-atome du cycle contenant un hétérocycle à six chaînons
20.
Additive manufacturing of cell-laden functional hydrogel and live cell constructs
Disclosed is a new 3D bioprinting method of soft polymeric material such as a hydrogel or elastomer and/or cells for scaffolds or devices with structures. The method utilizes in one aspect extrusion based printing of polymer solutions, hydrogels and cells referred as direct ink writing (DIW) or BioPlotting that is modified to offer break-through advantages. The method may utilize sequential printing of a photocurable polymer solution or matrix material, and a functional hydrogel and/or cells. Printing within or inside of a viscous non-cured layer is accomplished by printing cells directly into the functional hydrogel. The viscous layer does not need to be shear thinning and thus allows use of a wide variety of bioinks never before allowed because of shear thinning and recovery requirement of commonly utilized extrusion based embedded bioprinting approach. Complex printing patterns never before allowed for bioinks are now possible utilizing this new printing method.
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux
B29C 64/40 - Structures de support des objets en 3D pendant la fabrication, lesdites structures devant être sacrifiées après réalisation de la fabrication
B29K 105/00 - Présentation, forme ou état de la matière moulée
A binary CQD device is disclosed, which could include a MWIR-absorbing intraband CQD with another type of CQD. The binary CQD device could include a MWIR-absorbing intraband silver selenide (Ag2Se) CQD with a lead sulfide (PbS) CQD.
H01L 31/0352 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails caractérisés par leurs corps semi-conducteurs caractérisés par leur forme ou par les formes, les dimensions relatives ou la disposition des régions semi-conductrices
The present invention is directed to a method of producing active pharmaceutical ingredients (APIs). The method includes subjecting a reaction mixture with an API precursor to solvent extraction to produce a reactant stream with the API precursor. The method includes concentrating the API precursor in the reactant stream using at least one membrane. The method includes carrying out a reaction in a membrane reactor. The method includes separating the API precursor from the reaction stream using a separator. The method includes crystallizing the API precursor using a crystallizer to produce APIs.
C07C 213/06 - Préparation de composés contenant des groupes amino et hydroxy, amino et hydroxy éthérifiés ou amino et hydroxy estérifiés liés au même squelette carboné à partir d'hydroxyamines par des réactions impliquant l'éthérification ou l'estérification de groupes hydroxy
C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
23.
Artificial intelligence automation to improve network quality based on predicted locations
An artificial intelligence (AI) automation to improve network quality based on predicted locations is provided. A method can include training, by a first device comprising a processor and according to model configuration parameters received from a second device that is not the first device, a local machine learning model with training data derived from first location data collected by the first device; transmitting, by the first device to the second device, anonymized model features associated with the local machine learning model; in response to the transmitting of the anonymized model features, receiving, by the first device from the second device, an aggregated machine learning model; and estimating, by the first device, a future position of the first device by applying the aggregated machine learning model to second location data collected by the first device.
H04L 41/16 - Dispositions pour la maintenance, l’administration ou la gestion des réseaux de commutation de données, p. ex. des réseaux de commutation de paquets en utilisant l'apprentissage automatique ou l'intelligence artificielle
A three-dimensional Bragg grating may include a single colloidal crystal that includes a plurality of repeated layers of material having different refractive indexes. A sample cell for producing a volume Bragg grating may include an internal shape that forms at least one capillary cell having a flat surface and rounded edges. A method of producing a three-dimensional Bragg grating may include: suspending insoluble particles in a host fluid to form a suspension; and exposing the suspension to a sustained microgravity environment.
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
NEW JERSEY INSTITUTE OF TECHNOLOGY (USA)
Inventeur(s)
Guido-Sanz, Francisco
Anderson, Mindi
Diaz, Desiree
Talbert, Steven
Daher, Salam
Musa, Dahlia
Abrégé
A method of skin anomaly assessment, measurement, and monitoring is disclosed. The three-dimensional topology of a skin anomaly is digitally scanned, and a three-dimensional model of the skin anomaly is computationally constructed. From the three-dimensional model, length, width, depth, perimeter, and surface area measurements of the skin anomaly are derived. This information may be quantified by volume surface area, and/or distance along the surface of the anomaly, and measured against models of anticipated healing for medical monitoring and training.
Disclosed is a NP-μFEC (non-planar microfluidic electrochemical cell) or a reusable microfluidic electrochemical cell with a multiple three-dimensional (3D) non-planar interdigitated microelectrode array with minimal sample volume and enhanced electric fields penetration for highly sensitive electrochemical analysis. This demonstrates that cost-effective, easy-to-fabricate NP-μFEC can be an ideal new analytical lab-on-a-chip microfluidic platform for sensitive analyte inorganic heavy metals detection.
Disclosed is an electrified membrane flow-cell reactor system and method for nitrogen wastewater treatment and upcycling towards ammonia nitrogen without external acid/base consumption. This electrified membrane flow-cell reactor includes a cathodic membrane module having a gas-permeable or gas-exchange membrane and a cathodic catalytic layer, an anode, and a semi-permeable membrane between the cathodic and anodic chamber. Three chambers in the flow-cell reactor include (i) a cathode chamber for nitrate reduction and upcycling towards NH3, (ii) a trap chamber for NH3 capture and storage, and (iii) an anode chamber for H+ production and protonation of gaseous NH3 to NH4+. The cathodic membrane and anode are connected to an electric power source to provide a stable cathodic potential and enable electrode reactions. This method will continuously treat nitrate-containing wastewater and achieve simultaneous electrochemical nitrate reduction from the wastewater and ammonia recovery as ammonium salts in the trap chamber.
C02F 1/467 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par des procédés électrochimiques par électrolyse par désinfection électrochimique
C02F 1/461 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par des procédés électrochimiques par électrolyse
C05C 3/00 - Engrais contenant d'autres sels d'ammonium ou l'ammoniac lui-même, p. ex. ammoniac liquide
A method of purifying an organic solvent is provided. The method includes introducing an organic solvent into a membrane distillation system. The membrane distillation system includes a perfluorodioxole membrane. The method includes performing a distillation technique with the membrane distillation system using the perfluorodioxole membrane to treat and purify the organic solvent.
A treatment method and system using high-frequency ultrasound for treating a waste stream containing per- and polyfluoroalkyl substance (PFAS) is disclosed. The system has one or more reactors including one or more transducers configured to operating at one or more frequencies to destroy or mineralize the per- and polyfluoroalkyl substances (PFAS) in the waste stream using sonolysis.
C02F 1/36 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout au moyen d'oscillations mécaniques par des vibrations ultrasonores
C02F 1/68 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par addition de substances spécifiées, pour améliorer l'eau potable, p. ex. par addition d'oligo-éléments
B06B 1/06 - Procédés ou appareils pour produire des vibrations mécaniques de fréquence infrasonore, sonore ou ultrasonore utilisant l'énergie électrique fonctionnant par effet piézo-électrique ou par électrostriction
30.
Systems and methods for decoding of graph-based channel codes via reinforcement learning
Embodiments of the present disclosure relate to sequential decoding of moderate length low-density parity-check (LDPC) codes via reinforcement learning (RL). The sequential decoding scheme is modeled as a Markov decision process (MDP), and an optimized cluster scheduling policy is subsequently obtained via RL. A software agent is trained to schedule all check nodes (CNs) in a cluster, and all clusters in every iteration. A new RL state space model is provided that enables the RL-based decoder to be suitable for longer LDPC codes.
H03M 13/11 - Détection d'erreurs ou correction d'erreurs transmises par redondance dans la représentation des données, c.-à-d. mots de code contenant plus de chiffres que les mots source utilisant un codage par blocs, c.-à-d. un nombre prédéterminé de bits de contrôle ajouté à un nombre prédéterminé de bits d'information utilisant plusieurs bits de parité
Surgical marker systems and methods for delineating a lesion margin of a subject are provided. An example system includes a handheld probe device configured to capture an optical coherence tomography (OCT) image and a processor coupled to a memory. The handheld probe device includes a handheld probe including a fiber-optic probe assembly and a marker assembly. The processor is configured to: segment, by a neural network, each pixels of the OCT into different tissue-type categories; generate one or more feature vectors based at least in part on the segmented pixels; determine, by a one-class classifier, a boundary location in the OCT image between a normal tissue and an abnormal tissue of the tissue structure; and control the marker assembly to selectively create a visible label on a tissue location of the subject, the tissue location corresponding to the boundary location.
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
G06T 1/00 - Traitement de données d'image, d'application générale
G06V 10/26 - Segmentation de formes dans le champ d’imageDécoupage ou fusion d’éléments d’image visant à établir la région de motif, p. ex. techniques de regroupementDétection d’occlusion
G06V 10/774 - Génération d'ensembles de motifs de formationTraitement des caractéristiques d’images ou de vidéos dans les espaces de caractéristiquesDispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p. ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]Séparation aveugle de source méthodes de Bootstrap, p. ex. "bagging” ou “boosting”
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
32.
Communication Systems and Methods for Validation of a Transaction Via Consensus in A Distributed Network Environment
Beijing Wodong Tianjun Information Technology Co., Ltd. (Chine)
New Jersey Institute of Technology (USA)
Institute of Software, Chinese Academy of Sciences (Chine)
Inventeur(s)
Zhai, Xinlei
Tang, Qiang
Lu, Zhenliang
Xu, Jing
Zhang, Zhenfeng
Guo, Bingyong
Abrégé
Described in detail herein is a system for determining the validity of a transaction in a distributed network environment. The system includes a plurality of peer servers. The system broadcast a first transaction to the plurality of peer servers. The system further elects at least one peer leader from the plurality of peer servers. The system further broadcasts a first set of indices associated with a first subset of transactions, received from the plurality of peer servers, to one or more of the plurality of peer servers. The system further executes a first instance of a binary agreement protocol based at least in part on a second subset of indices associated with a second subset of the transactions. The system further outputs a consensus vector comprising one or more of the transactions.
Exemplary embodiments in desalination by direct contact membrane distillation present a cylindrical cross-flow module containing high-flux composite hydrophobic hollow fiber membranes. The present embodiments are directed to a model that has been developed to describe the observed water production rates of such devices in multiple brine feed introduction configurations. The model describes the observed water vapor production rates for different feed brine temperatures at various feed brine flow rates. The model flux predictions have been explored over a range of hollow fiber lengths to compare the present results with those obtained earlier from rectangular modules which had significantly shorter hollow fibers.
A method is disclosed for 3D printing thermally curable polymeric inks and their composites for scaffolds or devices. In this method, an extrusion based direct ink writing printing technology was used. The method includes an in-situ curing process and print layer height adjustment steps after each print layer to compensate for shrinkage during a thermal treatment step.
B29C 64/118 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux utilisant un matériau filamentaire mis en fusion, p. ex. modélisation par dépôt de fil en fusion [FDM]
A medical drug devices for transdermal drug delivery systems (TDDS) comprising a novel iontophoretic polymeric microneedle device and its use in administration of drugs.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
Devices and methods to measure cells and/or tissue's contractile force are disclosed. Included is a mount with rigid, and non-rigid posts sized to flex. Determined is force exerted by contractile cells and tissues in a multiwell plate. The device is designed to fit inside individual wells with posts directed downwards. Posts are attached to a 3D printed circular mount with tabs for depth within the well. The mount has a window for medium changes while the device is positioned inside the well. The cells are seeded within a hydrogel. As the hydrogel condenses, cells/tissue wrap around the post's outside pulling non-rigid post toward rigid post. Inverted light microscope is used to determine deflection of non-rigid post inside the multiwell plate. Movement of the non-rigid post is measured using an acrylic ruler on an underside of the multiwell plate. Contractile forces of cells/tissue are determined using cantilever mechanics.
A method is disclosed for 3D printing of soft polymeric material such as a hydrogel or elastomer for scaffolds or devices with embedded channels with tunable shape and size such as a channel inner diameter). The method utilizes extrusion based printing of polymer solutions usually referred as direct ink writing (DIW) or BioPlotting, and requires sequential printing of a photocurable polymer solution, herein, referred as the matrix material, and a sacrificial polymer solution that may dissolve in an aqueous media.
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux
A61L 27/50 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
B29C 64/40 - Structures de support des objets en 3D pendant la fabrication, lesdites structures devant être sacrifiées après réalisation de la fabrication
Board of Regents, The University of Texas System (USA)
Government of the United States, as represented by the Secretary of the Air Force (USA)
New Jersey Institute of Technology (USA)
Inventeur(s)
Xu, Shouhuai
He, Songlin
Ficke, Eric
Pritom, Mir Mehedi Ahsan
Chen, Huashan
Tang, Qiang
Chen, Qian
Pendleton, Marcus
Njilla, Laurent
Abrégé
The present disclosure presents blockchain-based cyber security management systems and related methods. One such method comprises obtaining cyber intelligence input data from a cyber defender computing device, wherein the cyber defender computing device manages network security of a network, wherein the cyber intelligence input data identifies a cyber attacker or a victim of a cyber attack on the network; executing one or more Cyber Security Management (CSM) functions with the cyber intelligence input data received from the cyber defender computing device and cyber data stored in the blockchain ledger, wherein the cyber data stored in the blockchain ledger provides details on a cyber attack on a network that is managed by another cyber defender computing device; and outputting an alert to the cyber defender computing device with a potential cyber attacker or potential victim of the cyber attack on the network managed by the cyber defender computing device.
An example porous composite membrane for solvent extraction is provided. The porous composite membrane includes a Janus membrane with a first side and a second side opposing the first side. The first side exhibits hydrophobic characteristics and the second side exhibits hydrophilic characteristics. At least one of the first side or the second side is sized to perform nondispersive membrane solvent extraction.
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétésProcédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
The disclosure relates to a method for identification via channels in a system having a plurality of data processing devices (10, 12, 13, 14). The method comprises selecting, in a first data processing device (10), an identifier indicative of a target second data processing device (12) of a plurality of second data processing devices (12, 13, 14); determining, in the first data processing device (10), an outer codeword from the identifier using an outer code comprising a first outer code and a second outer code; determining, in the first data processing device (10), an optical orthogonal codeword of weight W from the outer codeword using an optical orthogonal code; determining, in the first data processing device (10), a randomly selected codeword from a set of W code words of an error correction code assigned to the optical orthogonal codeword; and emitting the selected codeword from the first data processing device (10) via a channel. Further, a computer program product and a system for identification via channels are provided.
H03M 13/37 - Méthodes ou techniques de décodage non spécifiques à un type particulier de codage prévu dans les groupes
H03M 13/01 - Hypothèses de base sur la théorie du codageLimites de codageMéthodes d'évaluation de la probabilité d'erreurModèles de canauxSimulation ou test des codes
H03M 13/51 - Codes à poids constantCodes n parmi mCodes Berger
H03M 13/29 - Codage, décodage ou conversion de code pour détecter ou corriger des erreursHypothèses de base sur la théorie du codageLimites de codageMéthodes d'évaluation de la probabilité d'erreurModèles de canauxSimulation ou test des codes combinant plusieurs codes ou structures de codes, p. ex. codes de produits, codes de produits généralisés, codes concaténés, codes interne et externe
A composition, and method for a targeted drug delivery is disclosed in treating central nervous system injury, including blast hearing loss, traumatic brain injury (TBI) and the like, by administering a subject with nanoparticle-based minocycline formulations. The formulation contains nanoparticles encapsulating minocycline for neuroprotective effect in TBI. Albumin nanoparticle-based minocycline formulations provide enhanced delivery to brain, and reduced toxicity at minimal dosage for treating a subject suffering from central nervous system injury including blast induced traumatic brain injury (bTBI). Nanoparticle administered at minimal dose in rat blast TBI model crossed blood-brain barrier (BBB) and enhanced therapeutic concentration compared to free minocycline. Provided is an effective and safe minocycline delivery in TBI with minimal or no toxicity for neuroprotective therapy. Studies indicate performance for behavioral (acute and chronic), pathological (chronic) and hearing loss mitigation using the disclosed drug and nanoparticles in rat moderate bTBI model.
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
42.
Relative Quantitation Using Electrochemical Mass Spectrometry
A method for relative quantification of organic and biological compounds by electrochemical mass spectrometry is disclosed. The method involves using electrochemistry (EC) in a mass spectrometry (MS)-based relative quantitative analysis. In this method, isotope-labeled standards or running calibration curves are not employed. A quantification method could include the steps of subjecting a sample analyte to liquid chromatography or electrophoresis separation, followed by an electrochemical oxidation or reduction in an electrochemical cell, and then mass spectrometric detection.
Materials for binding per- and polyfluoroalkyl substances (PFAS) are disclosed. A fluidic device comprising the materials for detection and quantification of PFAS in a sample is disclosed. The fluidic device may be configured for multiplexed analyses. Also disclosed are methods for sorbing and remediating PFAS in a sample. The sample may be groundwater containing, or suspected of containing, one or more PFAS.
B01J 27/188 - PhosphoreSes composés avec de l'arsenic, de l'antimoine, du bismuth, du vanadium, du niobium, du tantale, du polonium, du chrome, du molybdène, du tungstène, du manganèse, du technétium ou du rhénium avec du chrome, du molybdène, du tungstène ou du polonium
B01J 27/195 - PhosphoreSes composés avec de l'arsenic, de l'antimoine, du bismuth, du vanadium, du niobium, du tantale, du polonium, du chrome, du molybdène, du tungstène, du manganèse, du technétium ou du rhénium avec du vanadium, du niobium ou du tantale
B01J 35/00 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général
A62D 3/115 - Dégradation ou conversion électrolytique
A62D 3/40 - Procédés pour rendre les substances chimiques nuisibles inoffensives ou moins nuisibles en effectuant un changement chimique dans les substances par chauffage pour effectuer une modification chimique, p. ex. par pyrolyse
A62D 3/38 - Procédés pour rendre les substances chimiques nuisibles inoffensives ou moins nuisibles en effectuant un changement chimique dans les substances par réaction avec des agents chimiques par oxydationProcédés pour rendre les substances chimiques nuisibles inoffensives ou moins nuisibles en effectuant un changement chimique dans les substances par réaction avec des agents chimiques par combustion
C02F 1/72 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par oxydation
C02F 1/30 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par irradiation
G01N 27/48 - Systèmes utilisant la polarographie, c.-à-d. la mesure des variations d'intensité sous une tension qui varie lentement
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtrationAbsorbants ou adsorbants pour la chromatographieProcédés pour leur préparation, régénération ou réactivation contenant une substance organique
C02F 1/32 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par irradiation par la lumière ultraviolette
C02F 1/58 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par élimination de composés spécifiés dissous
G01N 27/07 - Structure des récipients de mesureÉlectrodes pour ces récipients
G01N 27/22 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la capacité
The present invention is directed to a method of producing active pharmaceutical ingredients (APIs). The method includes subjecting a reaction mixture with an API precursor to solvent extraction to produce a reactant stream with the API precursor. The method includes concentrating the API precursor in the reactant stream using at least one membrane. The method includes carrying out a reaction in a membrane reactor. The method includes separating the API precursor from the reaction stream using a separator. The method includes crystallizing the API precursor using a crystallizer to produce APIs.
C07C 213/06 - Préparation de composés contenant des groupes amino et hydroxy, amino et hydroxy éthérifiés ou amino et hydroxy estérifiés liés au même squelette carboné à partir d'hydroxyamines par des réactions impliquant l'éthérification ou l'estérification de groupes hydroxy
C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
A membrane distillation (MD) system consisting of a membrane module and carbon nanotube immobilized membrane for organic solvent separation is disclosed. The MD module includes a feed inlet and outlet, a sweep gas inlet, and a sweep gas outlet. Thermostats are positioned at the feed inlet and outlet to measure the change in temperature. Preferential sorption of the organic on carbon nanotube immobilized membrane contributes to enhanced solvent removal of the MD system. A pervaporation (PV) system consisting of a membrane module and polyvinyl alcohol (PVA) mixed matrix membranes with graphene oxide (GO)—carbon nanotubes (CNTs) for enhanced purification of the alcohol solution after membrane distillation to remove trace amount of water is disclosed.
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétésProcédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
C02F 1/44 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par dialyse, osmose ou osmose inverse
Disclosed is a new 3D bioprinting method of soft polymeric material such as a hydrogel or elastomer and/or cells for scaffolds or devices with structures. The method utilizes in one aspect extrusion based printing of polymer solutions, hydrogels and cells referred as direct ink writing (DIW) or BioPlotting that is modified to offer break-through advantages. The method may utilize sequential printing of a photocurable polymer solution or matrix material, and a functional hydrogel and/or cells. Printing within or inside of a viscous non-cured layer is accomplished by printing cells directly into the functional hydrogel. The viscous layer does not need to be shear thinning and thus allows use of a wide variety of bioinks never before allowed because of shear thinning and recovery requirement of commonly utilized extrusion based embedded bioprinting approach. Complex printing patterns never before allowed for bioinks are now possible utilizing this new printing method.
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux
B29C 64/40 - Structures de support des objets en 3D pendant la fabrication, lesdites structures devant être sacrifiées après réalisation de la fabrication
A pervaporation apparatus and method for liquid mixture separation are disclosed. The pervaporation disclosed utilizes an interfacial-heating membrane utilizing induction heating to provide temperature differences across the membrane for driving liquid mixture separation. The pervaporation system may include an electromagnetic induction heating device that is placed close to or encapsulated in a membrane module wherein one or more membranes with surfaces containing ferromagnetic or other induction-responsive materials. The membrane surface generates localized heat owing to the presence of a ferromagnetic composition that converts electric energy from an induction source to thermal energy. The ferromagnetic composition could include, without limitation, metals, metal alloys, composite materials, nanocomposite materials, nanoparticles, meshes, and combinations thereof.
B01D 61/36 - PervaporationDistillation à membranesPerméation liquide
B01D 69/02 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétésProcédés spécialement adaptés à leur fabrication caractérisées par leurs propriétés
A treatment method and system using high-frequency ultrasound for treating a waste stream containing per- and polyfluoroalkyl substance (PFAS) is disclosed. The system has one or more reactors including one or more transducers configured to operating at one or more frequencies to destroy or mineralize the per- and polyfluoroalkyl substances (PFAS) in the waste stream using sonolysis.
A23L 5/30 - Traitement physique, p. ex. par des moyens électriques ou magnétiques, par énergie ondulatoire ou par irradiation
B01J 19/08 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaireAppareils à cet usage
B02C 19/18 - Utilisation d'effets physiques auxiliaires aidant la désagrégation, p. ex. ultrasons, irradiation
B06B 1/06 - Procédés ou appareils pour produire des vibrations mécaniques de fréquence infrasonore, sonore ou ultrasonore utilisant l'énergie électrique fonctionnant par effet piézo-électrique ou par électrostriction
C02F 1/36 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout au moyen d'oscillations mécaniques par des vibrations ultrasonores
C08J 3/28 - Traitement par ondes énergétiques ou par rayonnement de particules
49.
Systems and methods for privacy-reserving data hiding
Described in detail herein is a method for encrypting or encoding time-stamped location data associated with a computing device. The method converts time and location information associated with the computing device into a vector format. The method generates a code vector based on the converted time and location vector. The method sorts entries in the code vector based at least in part on a predetermined ordering scheme. The method executes a random modification to each of the sorted entries. The method compares the code vector to at least one other code vector associated with another computing device. The method identifies other code vectors within a specified distance of the given code vector. The method concludes that the computing device and the at least one other computing device were in proximity to each other during a time period corresponding to the time information.
G06F 21/62 - Protection de l’accès à des données via une plate-forme, p. ex. par clés ou règles de contrôle de l’accès
H03M 13/19 - Correction d'une seule erreur sans utiliser les propriétés particulières des codes cycliques, p. ex. codes de Hamming, codes de Hamming étendus ou généralisés
An example system for detecting pipe defects is provided. The system includes a transmitter, a receiver and a processing device. The transmitter is oriented to transmit Terahertz (THz) waveform pulses towards at least one of an outer surface of a pipe or an inner surface of the pipe. The receiver is oriented to receive reflected Terahertz (THz) waveform pulses from at least one of the outer surface of the pipe or the inner surface of the pipe. The processing device configured is to receive as input the Terahertz (THz) waveform pulses transmitted from the transmitter and the reflected Terahertz (THz) waveform pulses received by the receiver and, based on the received input, determine if a defect in the pipe exists.
G01N 21/88 - Recherche de la présence de criques, de défauts ou de souillures
G01N 21/3581 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant la lumière de l'infrarouge lointainCouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge en utilisant un rayonnement térahertz
G01M 3/38 - Examen de l'étanchéité des structures ou ouvrages vis-à-vis d'un fluide par utilisation de la lumière
Disclosed is a new strategy, composition, and method for a self-assembling peptides (SAP) that will self-assemble atop COVID-19 for immune destruction and act as a functional COVID-19 opsonin. The designed self-assembling peptides bind and assemble atop SARS-CoV-2—providing a new mechanism of infection abrogation. One benefit is avoidance of side effects that other formulations or repurposed drugs contain. Other feature of this technology include: (a) (SAP) are composed of L-amino acids that are highly biocompatible sub-Q, IM and IV (no adverse reaction for 10% blood volume replacement with 1 w % peptide in mice or rats); (b) Highly targeted approach that binds to viral particles preventing side effects; (c) SAP are intrinsically biodegradable and endocytosed; (d) SAP bound COVID-19 may promote engulfment, clearance, and antigen presentation (for immunity development); and (e) targeting the spike protein with SAP may allow treatment of other coronaviruses.
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
G16B 15/00 - TIC spécialement adaptées à l’analyse de structures moléculaires bidimensionnelles ou tridimensionnelles, p. ex. relations structurelles ou fonctionnelles ou alignement de structures
52.
INJECTABLE FORMULATIONS OF ANESTHETICS FOR ANY PATHOLOGICAL PAIN
An injectable formulation for a sustained-release of a local anesthetic is provided. The formulation comprises a pharmaceutically effective amount of a local anesthetic encapsulated into polymeric particles having a diameter from about 1 μm to about 4 μm. Such formulation prolongs analgesic effect, decreases toxicity, and allows loading larger doses, and at the same time is injectable directly at a patient's body site of the interest without generating a surgical wound. Methods of use and preparation are also provided.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A61K 31/4168 - 1,3-Diazoles ayant un atome d'azote lié en position 2, p. ex. clonidine
A61K 31/4174 - Arylalkylimidazoles, p. ex. oxymétazoline, naphazoline, miconazole
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/135 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone
A61K 31/5517 - 1,4-Benzodiazépines, p. ex. diazépam condensées avec des cycles à cinq chaînons ayant l'azote comme hétéro-atome d'un cycle, p. ex. imidazobenzodiazépines, triazolam
A61K 33/00 - Préparations médicinales contenant des ingrédients actifs inorganiques
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/46 - Aza-8-bicyclo[3.2.1]octaneSes dérivés, p. ex. atropine, cocaïne
BEIJING WODONG TIANJUN INFORMATION TECHNOLOGY CO., LTD. (Chine)
NEW JERSEY INSTITUTE OF TECHNOLOGY (USA)
INSTITUTE OF SOFTWARE, CHINESE ACADEMY OF SCIENCES (Chine)
Inventeur(s)
Zhai, Xinlei
Tang, Qiang
Lu, Zhenliang
Xu, Jing
Zhang, Zhenfeng
Guo, Bingyong
Abrégé
Described in detail herein is a system for determining the validity of a transaction in a distributed network environment. The system includes a plurality of peer servers. The system elects a set of peer leaders from the plurality of peer servers. The set of peer leaders broadcast a first set of indices associated with a first subset of transactions, received from the plurality of peer servers, to one or more of the plurality of peer servers. The set of elected peer leaders execute a first instance of a binary agreement protocol based at least in part on a second subset of indices associated with a second subset of the transactions. The set of elected peer leaders output a consensus vector comprising one or more of the transactions.
BEIJING WODONG TIANJUN INFORMATION TECHNOLOGY CO., LTD. (Chine)
NEW JERSEY INSTITUTE OF TECHNOLOGY (USA)
INSTITUTE OF SOFTWARE, CHINESE ACADEMY OF SCIENCES (Chine)
Inventeur(s)
Zhai, Xinlei
Tang, Qiang
Lu, Zhenliang
Xu, Jing
Zhang, Zhenfeng
Guo, Bingyong
Abrégé
Described in detail herein is a system for determining the validity of a transaction in a distributed network environment. The system includes a plurality of peer servers. The system broadcast a first transaction to the plurality of peer servers. The system further elects at least one peer leader from the plurality of peer servers. The system further broadcasts a first set of indices associated with a first subset of transactions, received from the plurality of peer servers, to one or more of the plurality of peer servers. The system further executes a first instance of a binary agreement protocol based at least in part on a second subset of indices associated with a second subset of the transactions. The system further outputs a consensus vector comprising one or more of the transactions.
G06F 11/18 - Détection ou correction d'erreur dans une donnée par redondance dans le matériel en utilisant un masquage passif du défaut des circuits redondants, p. ex. par logique combinatoire des circuits redondants, par circuits à décision majoritaire
55.
Nano Carbon Immobilized Membranes for Selective Membrane Distillation
A membrane distillation (MD) system includes a membrane module and reduced graphene oxide-carbon nanotube immobilized membrane for organic solvent separation. The MD module could include a feed inlet and outlet, a sweep gas inlet, and a sweep gas outlet. Thermostats are positioned at the feed inlet and outlet to measure the change in temperature. Preferential sorption of the organic, specifically tetrahydrofuran (THF), on a hybrid reduced graphene oxide-carbon nanotube immobilized membrane contributes to enhanced solvent removal of the MD system.
One aspect of the disclosure describes a lipid conjugated cationic molecule. Other aspects of the disclosure describes nanoparticle delivery systems and methods of making the systems are disclosed. An embodiment of the nanoparticle delivery system has sustained gene delivery properties, the nanoparticle delivery system can be synthesized using biodegradable and biocompatible polymers via self-assembly. The nanoparticle delivery system comprises a plurality of nanoparticle depots, each of which has a particle-in-particle structure, and is composed of a polymeric nanoparticle, which encapsulates cationic molecule/nucleic acid complexes, facilitating enhanced retention and prolonged release of the gene payload. The polymeric nanoparticle comprises a shell, and a nanocomplex of the cationic molecule and a polynucleotide, the nanocomplexes are distributed within the shell and/or embedded in the shell. Another embodiment of the nanoparticle delivery system has one or more nanocomplexes. The one or more nanocomplexes includes a lipid conjugated cationic molecule and a polynucleotide.
Exemplary embodiments relate to systems, methods, and apparatus to objectively assess binocular dysfunction for screening, diagnoses, and evaluation of vision/oculomotor function before, during, and after various forms of therapeutic interventions. Systems and methods diagnose and assess binocular dysfunction objectively and automatically, can render a visual stimulus on one or more displays, and can control accommodative and proximal vergence stimulation of a user's eyes.
A61B 3/08 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure subjective, c.-à-d. appareils de d’examen nécessitant la participation active du patient pour examen de vision binoculaire ou stéréoscopique, p. ex. pour le contrôle du strabisme
A61B 3/00 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux
A61B 3/032 - Dispositifs pour présenter des symboles ou des caractères d'épreuve, p. ex. projecteurs de mires
A61B 3/113 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G02B 30/36 - Stéréoscopes fournissant une paire stéréoscopique d'images séparées correspondant à des vues déplacées parallèlement du même objet, p. ex. visionneuses de diapositives 3D utilisant des éléments optiques réfractifs, p. ex. des prismes, dans le chemin optique entre les images et les observateurs
58.
Scan-less optically computed optical coherence tomography using a spatial light modulator
An optically computed optical coherence tomography (OC-OCT) technology is disclosed. The OC-OCT system performs depth resolved imaging by computing the Fourier transform of the interferometric spectra optically. The OC-OCT system modulates the interferometric spectra with Fourier basis function projected to a spatial light modulator and detects the modulated signal without spectral discrimination. The optical computation strategy enables volumetric OCT imaging without performing mechanical scanning and without the need for Fourier transform in a computer. OC-OCT performs Fourier transform signal processing optically, without the need of mechanical scanning, and before data acquisition unlike traditional OCT methods and systems. The scan-less OCT imaging is achieved through the use of spatial light modulator (SLM) that precisely manipulates light wave to generate output with desired amplitude and phase.
A suction assembly, toothbrush, and method are provided that suction fluids and debris resulting from brushing. The suction assembly includes a housing configured to couple to the toothbrush so that a portion extends around sides and a back of the toothbrush head and is spaced from the toothbrush head by a gap. The suction assembly further includes a vacuum pump, a collection reservoir, and one or more conduits that couple the vacuum pump, suction head portion, and collection reservoir to apply a suction around the toothbrush head through the gap and deposit suctioned material in the collection reservoir.
A46B 15/00 - Autres brossesBrosses avec aménagements additionnels
A46B 5/00 - Montures de brossesManches faisant corps avec la brosse
A46B 9/04 - Position ou disposition des soies par rapport à la surface de la monture, p. ex. inclinées, en rangées, en groupes pour les brosses à dents
A46B 13/02 - Brosses à monture commandée à entraînement mécanique
Systems and methods to remediate, degrade, and/or remove pollutants within various contaminated environmental solid media that includes contaminated soils and sediments, biosolids and slurries by subjecting a mixture of the contaminated solids and a liquid to acoustic cavitation generated by more than one type of ultrasonic device. One of the ultrasonic devices operates at a low frequency and the other ultrasonic device operates at a high frequency. The system advantageously provide an efficient, sustainable, and easy to handle approach to degrade contaminant, requiring only electrical energy.
B09C 1/06 - Régénération de sols pollués par des procédés thermiques
B09C 1/08 - Régénération de sols pollués par des procédés chimiques
B06B 1/06 - Procédés ou appareils pour produire des vibrations mécaniques de fréquence infrasonore, sonore ou ultrasonore utilisant l'énergie électrique fonctionnant par effet piézo-électrique ou par électrostriction
B06B 3/00 - Procédés ou appareils spécialement adaptés pour transmettre des vibrations mécaniques de fréquence infrasonore, sonore ou ultrasonore
61.
Methods and devices for high-capacity flexible, printable, and conformal periodate and iodate batteries
H01M 4/38 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'éléments simples ou d'alliages
H01M 4/58 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés inorganiques autres que les oxydes ou les hydroxydes, p. ex. sulfures, séléniures, tellurures, halogénures ou LiCoFyEmploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de structures polyanioniques, p. ex. phosphates, silicates ou borates
H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p. ex. liants, charges
H01M 4/74 - Grillage ou matériau tisséMétal déployé
H01M 50/489 - Séparateurs, membranes, diaphragmes ou éléments d’espacement dans les cellules caractérisés par leurs propriétés physiques, p. ex. degré de gonflement, hydrophilicité ou propriétés pour court-circuiter
An injectable peptide-based hydrogel is disclosed that incorporates a peptide inhibitor of proprotein convertase subtilisn/kexin type 9. The hydrogel is a polymer composed of the 13-amino-acid protein, Pep2-8, (TVFTSWEEYLDWV) attached to a self-assembling peptide of the ABA block structure (ESLSLSLSLSLSLEG) to generate the repeating multidomain peptide sequence (ESLSLSLSLSLSLEGTVFTSWEEYLDWV).
Embodiments of microfluidic systems and methods of manufacturing are described herein, which utilize an automated microfluidic plumbing technology with addressable ports capable of minimally disruptive additive and subtractive (including probing) cell and/or fluid manipulation at any desired location(s) within living cultures. The addressable microfluidic ports may be integrated throughout cell cultures in microfluidic systems for microfluidic tissue scaffolds, in two- or three-dimensional spatial arrangements. The addressable microfluidic ports may be used for controlling and/or monitoring cell behavior over time at different user-selected locations within cell cultures. Also provided are methods for fabricating such microfluidic devices and microfluidic tissue scaffolds.
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
An example method of preparing spherical composite powders is provided. The method includes introducing one or more starting material powders into an agitation mill. The method includes introducing a process control agent into the agitation mill, the process control agent including at least two immiscible liquids. The method includes agitating and milling the one or more starting material powders and the process control agent with the agitation mill to produce substantially spherical composite powders.
B02C 23/36 - Addition de fluide, dans un but autre que celui de broyer ou de désagréger par l'énergie du fluide la zone de broyage ou de désagrégation étant immergée dans un liquide
C06B 33/00 - Compositions contenant des particules de métal, alliage, bore, silicium, sélénium ou tellure avec au moins un matériau fournissant de l'oxygène, qui est soit un oxyde métallique, soit un sel, organique ou inorganique, susceptible de donner un oxyde métallique
C06B 21/00 - Appareils ou méthodes pour la mise en œuvre des explosifs, p. ex. mise en forme, coupage, séchage
B02C 17/18 - Désagrégation au tonneau, c.-à-d. par des appareils constitués par une cuve où les produits à désagréger sont chargés, avec ou sans éléments particuliers de désagrégation tels que billes ou boulets Parties constitutives
65.
FLUIDIC IMPEDANCE PLATFORM FOR IN-SITU DETECTION AND QUANTIFICATION OF PFAS IN GROUNDWATER
Materials for binding per- and polyfluoroalkyl substances (PFAS) are disclosed. A fluidic device comprising the materials for detection and quantification of PFAS in a sample is disclosed. The fluidic device may be configured for multiplexed analyses. Also disclosed are methods for sorbing and remediating PFAS in a sample. The sample may be groundwater containing, or suspected of containing, one or more PFAS.
2 is demonstrated. Novel 3D-printed reserve battery casing designs comprising replaceable electrodes also disclosed. Batteries featuring an ion-exchange membrane dual-electrolyte design are disclosed. Periodate based dry cell batteries utilizing polymer electrolytes are also disclosed.
H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p. ex. liants, charges
H01M 4/60 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs de composés organiques
H01M 4/485 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques d'oxydes ou d'hydroxydes mixtes pour insérer ou intercaler des métaux légers, p. ex. LiTi2O4 ou LiTi2OxFy
67.
System and method for multi-level vacuum generation and storage
A vacuum generation system and method utilizes a dual-action piston-cylinder vacuum generation system to evacuate a vacuum storage. Saturated steam of higher than ambient pressure is inserted into a condensation cylinder with two chambers separated by a movable piston. Steam moves the piston to fill one chamber while expel gaseous content and condensate out of the other chamber. Steam is then condensed to a rough vacuum (RV) state by cooling. By repeated operations of inserting and condensing steam in each chamber alternatively, a sustained vacuum generation is achieved. A multi-level vacuum storage is also disclosed with a high vacuum (HV) storage placed inside a rough vacuum (RV) storage to reduce leakage as well as mechanical stresses. The vacuum generation system and method is extended for creating a prime mover or actuator to drive vacuum pumps maximizing thermal energy usage for increased vacuuming capacity.
F04B 35/00 - Pompes à piston spécialement adaptées aux fluides compressibles et caractérisées par les moyens d'entraînement de leurs organes de travail ou par leur combinaison avec les machines motrices ou moteurs qui les entraînent ou bien par leurs adaptations à cet effet, non prévues ailleurs
F04B 39/06 - RefroidissementChauffagePrévention du gel
F04B 27/00 - Pompes multicylindres spécialement adaptées aux fluides compressibles et caractérisées par le nombre ou la disposition des cylindres
68.
Method For Computing Fastest Route On Road Networks With Dynamic Traffic Information
A method and system that utilizes an admissible heuristic to determine the fastest-path between two points on a road map is disclosed. The method and system are based in part on a set of separators disposed on the map and represented by line segments, either independent or organized into hierarchical tree structures and based on recursive spatial subdivision. A preprocessing step computes a vector of values per road junction based on the separators that is then stored with the map and used to efficiently compute a high-quality heuristic to be used at a query stage. The heuristic scales well to any map size, resulting in a very efficient determination of fastest-path queries between points at all distances. The implementation is economically feasible and the resulting query speeds are significantly faster than other known heuristics and other state-of-the-art systems used for computing fastest-paths on maps.
G01C 21/34 - Recherche d'itinéraireGuidage en matière d'itinéraire
G06F 16/9537 - Recherche à dépendance spatiale ou temporelle, p. ex. requêtes spatio-temporelles
G06F 16/27 - Réplication, distribution ou synchronisation de données entre bases de données ou dans un système de bases de données distribuéesArchitectures de systèmes de bases de données distribuées à cet effet
G06F 16/901 - IndexationStructures de données à cet effetStructures de stockage
A medical drug devices for transdermal drug delivery systems (TDDS) comprising a novel iontophoretic polymeric microneedle device and its use in administration of drugs.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
Exemplary embodiments in desalination by direct contact membrane distillation present a cylindrical cross-flow module containing high-flux composite hydrophobic hollow fiber membranes. The present embodiments are directed to a model that has been developed to describe the observed water production rates of such devices in multiple brine feed introduction configurations. The model describes the observed water vapor production rates for different feed brine temperatures at various feed brine flow rates. The model flux predictions have been explored over a range of hollow fiber lengths to compare the present results with those obtained earlier from rectangular modules which had significantly shorter hollow fibers.
Systems, methods, and non-transitory computer-readable media are provided for modifying the manner in which virtual reality media developed for the general public is rendered on a virtual reality display to provide vision therapy to a user, the method comprising. Virtual reality media to be rendered in a virtual reality display is processed and one or more parameters are received from a virtual reality display. The one or more parameters specify the manner in which the virtual reality media is to be rendered on the virtual reality display. At least one of the one or more parameters is modified to alter the manner in which the virtual reality media is render on the virtual reality display after the one or more parameters are received and prior to transmission of the virtual reality media to the virtual reality display. The virtual reality media on the virtual reality display based on the at least one of the one or more parameters that have been modified to increases an effect of the vergence- accommodation conflict of the user viewing the virtual reality display.
An apparatus and method to detect disease-specific antigens assists in disease diagnosis. Point-of-care (POC) micro biochip incorporates at least one hydrophilic microchannel for controlled and self-driven flow of body fluid. Metallic nano-interdigitated electrodes disposed within the channels give enhanced sensitivity detection. Microchannel controls flow and amplifies a capillary effect. Electrodes are fabricated on microchannel surface to detect biomolecular interactions. When a sample flows through microchannel, disease-specific antigens from the sample form antigen-antibody complex with antibodies immobilized on electrodes. Antigen-antibody interaction is detected via an electrical change in the biochip's nano circuit. Each electrode may include a different antibody to detect different antigens. Capacitance during antigen-antibody interaction without microfluidic flow is higher than with microfluidic flow due to immobilized antibodies instability on sensing surface caused by shear stress. POC biochip provides nano level detection of many disease-specific antigens of any type based on micro volume or single drop sized sample.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
G01N 27/02 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance
G01N 27/22 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la capacité
73.
INJECTABLE FORMULATIONS OF ANESTHETICS FOR ANY PATHOLOGICAL PAIN
An injectable formulation for a sustained-release of a local anesthetic is provided. The formulation comprises a pharmaceutically effective amount of a local anesthetic encapsulated into polymeric particles having a diameter from about 1 μm to about 4 μm. Such formulation prolongs analgesic effect, decreases toxicity, and allows loading larger doses, and at the same time is injectable directly at a patient's body site of the interest without generating a surgical wound. Methods of use and preparation are also provided.
An injectable peptide-based hydrogel is disclosed that incorporates a peptide inhibitor of proprotein convertase subtilisin/kexin type 9. The hydrogel is a polymer composed of the 13-amino-acid protein, Pep2-8, (TVFTSWEEYLDWV) attached to a self-assembling peptide of the ABA block structure (ESLSLSLSLSLSLEG) to generate the repeating multidomain peptide sequence (ESLSLSLSLSLSLEGTVFTSWEEYLDWV).
A method is disclosed for 3D printing of soft polymeric material such as a hydrogel or elastomer for scaffolds or devices with embedded channels with tunable shape and size such as a channel inner diameter). The method utilizes extrusion based printing of polymer solutions usually referred as direct ink writing (DIW) or BioPlotting, and requires sequential printing of a photocurable polymer solution, herein, referred as the matrix material, and a sacrificial polymer solution that may dissolve in an aqueous media.
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p. ex. dépôt d’un cordon continu de matériau visqueux
B29C 64/40 - Structures de support des objets en 3D pendant la fabrication, lesdites structures devant être sacrifiées après réalisation de la fabrication
Energy packet switches (EPS) employing supercapacitors as storage provide aggregation and delivery of energy to users based on shared-capacitance in a digital power grid. The EPS aggregates energy from one or multiple energy sources, stores and dispatches the energy in discrete amounts as energy packets to one or multiple users. The payload of the energy packet is adjusted by the voltages of the supercapacitors which are used as energy containers for both the EPS and the users. The EPS has a control plane where data transmitted is used to control the operation of the EPS, and a power plane to receive and transmit energy between ports. The power and data planes work in parallel and with a parallel data network. Control and management of the EPS are based on a request-grant transport protocol. The data network is used to receive energy requests and grants, and a granting scheme is used to select which loads are granted energy. By sending addresses of granted loads on the data network and energy on the energy grid, energy is delivered to addressed destinations.
H02M 5/22 - Transformation d'une puissance d'entrée en courant alternatif en une puissance de sortie en courant alternatif, p. ex. pour changement de la tension, pour changement de la fréquence, pour changement du nombre de phases sans transformation intermédiaire en courant continu par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande
H02M 3/335 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant continu avec transformation intermédiaire en courant alternatif par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrodes de commande pour produire le courant alternatif intermédiaire utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs
H02M 1/08 - Circuits spécialement adaptés à la production d'une tension de commande pour les dispositifs à semi-conducteurs incorporés dans des convertisseurs statiques
77.
System and method for a piezoelectric collagen scaffold
The present invention provides novel methods for poling piezoelectric materials, e.g., collagen, which are carried out in the absence of liquid media and at a relatively low temperature. The present invention also provides electroactive scaffolds comprising poled collagen for promoting cell growth and differentiation.
D01F 4/00 - Filaments, ou similaires, artificiels, à un seul composant, formés de protéinesLeur fabrication
H01L 41/253 - Traitement de dispositifs ou de leurs parties constitutives afin de modifier une propriété piézo-électrique ou électrostrictive, p.ex. les caractéristiques de polarisation, de vibration ou par réglage du mode
Pseudomonas biofilms. There is an inherent trade-off between the ability of the peptides to undergo nanofibrous self-assembly and having a high terminal charge density required for effective bactericidal efficacy. The self-assembled peptide hydrogel presented achieves a balance of these opposing factors. Also demonstrated is the applicability of the new composition in an injectable hydrogel formulation. A CASP platform may be useful for topical application and integration into medical coatings, grafts, devices, and prostheses, thereby reducing risk of bacterial infection and related failure.
Exemplary embodiments of the present disclosure relate to systems, methods, and apparatus to objectively assess binocular dysfunction for screening, diagnoses, and evaluation of vision/oculomotor function before, during, and after various forms of therapeutic interventions. Systems and methods of the present disclosure diagnose and assess binocular dysfunction objectively and automatically, can render a visual stimulus on one or more displays, and can control accommodative and proximal vergence stimulation of a user's eyes.
A61B 3/032 - Dispositifs pour présenter des symboles ou des caractères d'épreuve, p. ex. projecteurs de mires
A61B 3/08 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure subjective, c.-à-d. appareils de d’examen nécessitant la participation active du patient pour examen de vision binoculaire ou stéréoscopique, p. ex. pour le contrôle du strabisme
A61B 3/113 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
Exemplary embodiments of the present disclosure relate to systems, methods, and apparatus to objectively assess binocular dysfunction for screening, diagnoses, and evaluation of vision/oculomotor function before, during, and after various forms of therapeutic interventions. Systems and methods of the present disclosure diagnose and assess binocular dysfunction objectively and automatically, can render a visual stimulus on one or more displays, and can control accommodative and proximal vergence stimulation of a user's eyes.
A61B 3/032 - Dispositifs pour présenter des symboles ou des caractères d'épreuve, p. ex. projecteurs de mires
A61B 3/08 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure subjective, c.-à-d. appareils de d’examen nécessitant la participation active du patient pour examen de vision binoculaire ou stéréoscopique, p. ex. pour le contrôle du strabisme
A61B 3/113 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
CRRC ZHUZHOU ELECTRIC LOCOMOTIVE RESEARCH INSTITUTE CO., LTD. (Chine)
NEW JERSEY INSTITUTE OF TECHNOLOGY (USA)
Inventeur(s)
Feng, Jianghua
Taheri, Mina
Fan, Qiang
Ansari, Nirwan
Rojas-Cessa, Roberto
Zhou, Mengchu
Chen, Gaohua
Wang, Dajun
Tang, Jun
Zhang, Tairan
Abrégé
A method and a system for rail transit communication. The method includes: selecting a second target FSO transceiver from the FSO transceivers that are currently located within a signal coverage of a target FSO base station, in response to detecting that a first target free-space-optics (FSO) transceiver moves out of the signal coverage of the target FSO base station when data communication between the target FSO base station and the target user terminal is performed via the first target FSO transceiver, where the target FSO base station is one of the FSO base stations located on the rail; and maintaining the data communication between the target FSO base station and the target user terminal, by using the second target FSO transceiver. Handover among the base stations is reduced for user equipment, data communication rate is increased, and communication experience of passengers can be improved.
H04W 36/32 - La resélection étant déclenchée par des paramètres spécifiques par des données de localisation ou de mobilité, p. ex. des données de vitesse
H04L 29/08 - Procédure de commande de la transmission, p.ex. procédure de commande du niveau de la liaison
Improved diagnostic assemblies are provided. More particularly, the present disclosure provides improved and highly advantageous chip based diagnostic assemblies configured to detect human diseases (e.g., cancer) and/or pathogens, and related methods of use. In exemplary embodiments, the present disclosure provides for consumable micro- or nano-fluidic chip based diagnostic assemblies having visual biosensors, with the diagnostic assemblies using continuous flow-based micro- or nano-fluidic channels and antibody-based immuno-complex designs. In certain embodiments, the diagnostic assembly includes a self-sustainable and operable chip (e.g., thumb-sized chip) that is configured to be deployed as a single use consumable with a direct all-or-none readout as an output to satisfy a point of screening method to screen a population.
G01N 21/00 - Recherche ou analyse des matériaux par l'utilisation de moyens optiques, c.-à-d. en utilisant des ondes submillimétriques, de la lumière infrarouge, visible ou ultraviolette
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
83.
Radiative treatment of liquids in desalination and other membrane processes
Radiative heating and radiative feed modification systems and methods using microwave, radio frequency, magnetic field and ultrasound in membrane separation processes including membrane distillation (MD), reverse osmosis, forward osmosis and pervaporation are disclosed. Membrane distillation systems include at least one MD module, the MD module having at least one membrane, a feed inlet operable to receive a feed media and a feed outlet, and a radiative energy source operable to apply radiation to a feed media entering the feed inlet.
A microfluidic biochip for detecting disease antigens using gold nano interdigitated electrode circuit under a controlled self-driven flow condition is disclosed. The biochip incorporates hydrophilic microchannels for controlled self-driven flow and gold nano interdigitated electrodes for capacitive sensing with enhanced sensitivity. The biochip's microchannel has a surface treated with oxygen plasma to control microchannel surface hydrophilicity and flow rate of the biofluid sample. Carbon Nanotubes (CNTs) are utilized as an intermediate layer to enhance the binding capability to nano electrodes to enhance sensitivity. Due to the carboxylic groups of the CNTs, covalent bond binding between the antibodies and the CNTs allows the antibodies to adhere more readily on the surface of the electrodes. The quantity of antibodies attaching to the surface is increased due to the high surface to area ratio in CNTs.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
G01N 27/22 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la capacité
G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p. ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
85.
Compositions and methods for preparing polymeric films loaded with uniformly distributed drug particles
The present disclosure provides improved film based pharmaceutical products containing uniformly distributed drug or active agent particles (e.g., to achieve improved/excellent dissolution control including enhancing dissolution and bioavailability and/or product uniformity). More particularly, the present disclosure provides improved systems/methods for fabricating film based pharmaceutical products by utilizing higher surface modified micronized drug or active agent powders and film forming precursors and drying methods that accomplish improved/efficient drying and provide improved/excellent content uniformity of active pharmaceutical agents in the fabricated film based pharmaceutical products. In exemplary embodiments, the present disclosure provides for an easier means of directly incorporating dry micronized poorly water-soluble drugs or active agent particles (e.g., fenofibrate (“FNB”)) into films. The present disclosure demonstrates some advantages of direct incorporation of surface modified-micronized poorly water-soluble drug or active agent powders in film manufacturing.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p. ex. isosorbide condensés avec un carbocycle, p. ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/216 - Esters, p. ex. nitroglycérine, sélénocyanates d'acides carboxyliques d'acides ayant des cycles aromatiques, p. ex. bénactizyne, clofibrate
A medical drug devices for transdermal drug delivery systems (TDDS) comprising a novel iontophoretic polymeric microneedle device and its use in administration of drugs.
A61L 31/12 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
A61L 31/16 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
A medical drug devices for transdermal drug delivery systems (TDDS) comprising a novel iontophoretic polymeric microneedle device and its use in administration of drugs.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
A61L 31/12 - Matériaux composites, c.-à-d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
A61L 31/16 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
88.
System, device, and method to manufacture nanobubbles
Systems, devices, and methods for manufacturing nanobubbles are disclosed herein. In an embodiment, a nanobubble generator system includes a medium, wherein in the medium is a liquid medium or a semi-liquid medium. A device is immersed in the medium. The device includes a ceramic membrane having a first surface and an opposing second surface, and pores extending through the membrane from the first surface to the second surface, and a hydrophobic porous coating layer disposed on the first surface of the membrane. The system includes a gas source for providing a gas to the medium. In operation, the gas enters pores on the second surface of the membrane and exits the coating layer in the form of nanobubbles.
A liquid cell for in situ atomic force microscopy (AFM) measurement of a sample during filtration is provided. The liquid cell includes a cantilever probe; a cantilever holder to position the probe near a surface of a sample (e.g., a filtration membrane); a liquid cell housing provided to hold the sample and comprising an opening at the top; an upper part; a lower part; an internal cavity to contain a fluid; a fluid inlet passage located in the upper part; a first fluid outlet passage located in the upper part; and a second fluid outlet passage located in the lower part. A method of in situ atomic force microscopy (AFM) measurement of a sample during filtration in a liquid by using the liquid cell described herein is also provided.
A control system and method for an exoskeleton is provided. The control system utilizes the admittance control paradigm to provide a system and method for manipulating the exoskeleton using minimal force from the user. A force/torque sensor and servo motors are fitted onto a passive arm support, enabling motorized support for a user with upper extremity weaknesses. The exoskeleton may be used on any extremity. The admittance control paradigm includes an impedance control and an admittance control to allow a user with upper extremity weakness and limited independence to intuitively and with minimal force control the precise trajectory of their arms to achieve a greater degree of independence in activities of daily living. Unlike existing passive arm supports that utilize springs or rubber bands to balance the user's arm against gravity, this system provides more precise gravity compensation and minimizes the amount of force required to control the exoskeleton.
A61H 3/00 - Appareils pour aider des personnes handicapées à marcher
A61H 1/02 - Appareils d'exercice extenseurs ou de ployage
G06F 3/0338 - Dispositifs de pointage déplacés ou positionnés par l'utilisateurLeurs accessoires avec détection du déplacement linéaire ou angulaire limité d’une partie agissante du dispositif à partir d’une position neutre, p. ex. manches à balai isotoniques ou isométriques
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
A system and method for vacuum distillation and desalination contains integrated vacuum generation. Latent heat and a vacuum produced with steam condensation are used for distillation and desalination of liquid. The distillation and desalination system could comprise a spray evaporator and a condenser for receiving a feed stream for distillation or desalination. Produced are water flow condensate and concentrated liquid flow. A vacuum pump is actuated with condensation-induced dual-action piston-cylinder vacuum generation technology. The vacuum generator is configured to transfer latent heat from condensing steam vapor in its cylinder to the feed stream. Steam is also configured to transfer latent heat directly to the feed stream circulated through evaporators and condensers. A distillation and desalination method with active vacuuming and self-distillation in staggered multi-stage arrangement provides for efficient energy recovery. Use of multi-stage arrangement maximizes thermal energy usage for increased distillation capacity and applicability.
A chemical process to formulate conductive ink with low sintering temperature for inkjet printing is described and shown. The application of fabricated flexible conductive film on lithium ion batteries is also described. This chemical method and composition can remove the oxidation on metallic nanoparticle surface during ink fabrication and sintering processes. Etched metallic ions in the conductive ink are reduced and particles bridged while annealing printed patterns to achieve low temperature sintering at about 350° C. The chemical process can be applied on nickel materials that are excellent current collectors for lithium ion batteries due to high chemical stability especially at high charging-discharging potential of less than 3 Volts. Thermal decomposition and chemical reduction of silver salts are two methods disclosed for particle-free silver ink. Surfactant additive further make silver film more uniform and easier to be sintered.
H01M 4/505 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de manganèse d'oxydes ou d'hydroxydes mixtes contenant du manganèse pour insérer ou intercaler des métaux légers, p. ex. LiMn2O4 ou LiMn2OxFy
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p. ex. batteries à insertion ou intercalation de lithium dans les deux électrodesBatteries à l'ion lithium
H01M 10/0585 - Structure ou fabrication d'accumulateurs ayant uniquement des éléments de structure plats, c.-à-d. des électrodes positives plates, des électrodes négatives plates et des séparateurs plats
H01M 10/0569 - Matériaux liquides caracterisés par les solvants
H01M 10/0568 - Matériaux liquides caracterisés par les solutés
H01M 4/525 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer d'oxydes ou d'hydroxydes mixtes contenant du fer, du cobalt ou du nickel pour insérer ou intercaler des métaux légers, p. ex. LiNiO2, LiCoO2 ou LiCoOxFy
H01M 4/485 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques d'oxydes ou d'hydroxydes mixtes pour insérer ou intercaler des métaux légers, p. ex. LiTi2O4 ou LiTi2OxFy
93.
HOLLOW FIBER MEMBRANE MODULE FOR DIRECT CONTACT MEMBRANE DISTILLATION-BASED DESALINIZATION
Exemplary embodiments in desalination by direct contact membrane distillation present a cylindrical cross-flow module containing high-flux composite hydrophobic hollow fiber membranes. The present embodiments are directed to a model that has been developed to describe the observed water production rates of such devices in multiple brine feed introduction configurations. The model describes the observed water vapor production rates for different feed brine temperatures at various feed brine flow rates. The model flux predictions have been explored over a range of hollow fiber lengths to compare the present results with those obtained earlier from rectangular modules which had significantly shorter hollow fibers.
CRRC ZHUZHOU ELECTRIC LOCOMOTIVE RESEARCH INSTITUTE CO., LTD. (Chine)
NEW JERSEY INSTITUTE OF TECHNOLOGY (USA)
Inventeur(s)
Feng, Jianghua
Taheri, Mina
Fan, Qiang
Ansari, Nirwan
Rojas-Cessa, Roberto
Zhou, Mengchu
Chen, Gaohua
Wang, Dajun
Tang, Jun
Zhang, Tairan
Abrégé
A rail transit communication method and system, the method comprising: when a target free space optics (FSO) base station carries out data communication with a target user terminal by means of a first target FSO transceiver, if monitored that the first target FSO transceiver has moved out of the signal coverage range of the target FSO base station, screening one FSO transceiver from all of the FSO transceivers which are still currently located within the signal coverage range of the target FSO base station to serve as a second target FSO transceiver, the target FSO base station being any one FSO base station located on a rail; and using the second target FSO transceiver to continuously maintain a data communication process between the target FSO base station and the target user terminal. With the present application, the base station switching frequency of user equipment may be reduced, and the data communication rate is increased, thereby improving the communication experience of a passenger.
H04L 29/08 - Procédure de commande de la transmission, p.ex. procédure de commande du niveau de la liaison
H04W 36/32 - La resélection étant déclenchée par des paramètres spécifiques par des données de localisation ou de mobilité, p. ex. des données de vitesse
95.
ENHANCED SENSITIVITY AND SPECIFICITY FOR POINT-OF-CARE (POC) MICRO BIOCHIP
An apparatus and method to detect disease-specific antigens assists in disease diagnosis. Point-of- care (POC) micro biochip incorporates at least one hydrophilic microchannel for controlled and self-driven flow of body fluid. Metallic nano-interdigitated electrodes disposed within the channels give enhanced sensitivity detection. Microchannel controls flow and amplifies a capillary effect. Electrodes are fabricated on microchannel surface to detect biomolecular interactions. When a sample flows through microchannel, disease-specific antigens from the sample form antigen-antibody complex with antibodies immobilized on electrodes. Antigen-antibody interaction is detected via an electrical change in the biochip' s nano circuit. Each electrode may include a different antibody to detect different antigens. Capacitance during antigen-antibody interaction without microfluidic flow is higher than with microfluidic flow due to immobilized antibodies instability on sensing surface caused by shear stress. POC biochip provides nano level detection of many disease-specific antigens of any type based on micro volume or single drop sized sample.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
G01N 27/26 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant des variables électrochimiquesRecherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en utilisant l'électrolyse ou l'électrophorèse
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
96.
Method, system, and apparatus for treatment of binocular dysfunctions
Exemplary embodiments of the present disclosure relate to systems, methods, and apparatus for vision therapy. In exemplary embodiments a visual therapy game can be rendered on one or more displays and the visual therapy game can be controlled by eye movements of the user. Visual stimuli incorporated in the visual therapy game can be rendered to facilitate vergence eye movements for the treatment of binocular dysfunctions.
A61B 3/08 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure subjective, c.-à-d. appareils de d’examen nécessitant la participation active du patient pour examen de vision binoculaire ou stéréoscopique, p. ex. pour le contrôle du strabisme
A61B 3/113 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
A63F 13/213 - Dispositions d'entrée pour les dispositifs de jeu vidéo caractérisées par leurs capteurs, leurs finalités ou leurs types comprenant des moyens de photo-détection, p. ex. des caméras, des photodiodes ou des cellules infrarouges
97.
Method and device for testing the effectiveness of magnetic treatment of feed water for reducing mineral scaling in reverse osmosis processes
Government of the United States of America, The Bureau of Reclamation (USA)
New Jersey Institute of Technology (USA)
Inventeur(s)
Khusid, Boris
Guerra, Katherine L.
Leitz, Frank
Shen, Yueyang
Elele, Ezinwa O.
Lei, Qian
Abrégé
A benchtop device flow setup for determining the effectiveness of magnetic treatment of feed water for reducing mineral scaling includes two similar branches, both equipped with a reverse osmosis membrane and a pump that operate in the transient regime at the same flow rate and transmembrane pressure. The flow setup is further fed with a solution at the same level of supersaturation measured in a stirred reactor, however, only one branch exposes the feed to a magnetic field.
Molecularly Imprinted Polymers (MIPs) are utilized to detect diseases and minimize false negative/positive scenarios. MIPs are implemented on a nano-electric circuit in a biochip where interactions of MIPs and an Antigen/Antibody (AG/AB) are detected, and disease specific biomarkers diagnosed. Biomarker detection is achieved with interdigitated gold electrodes in a biochip's microchannel. Capacitance changes due to biomarker interaction with AG/AB electrode coating diagnose diseases in a microfluidic environment. Biofluid passes through the microchannel and exposed to the nanocircuit to generate a capacitance difference and diagnose any specific disease in the biofluid sample. Blood capillary flow in a microchannel curved section experience centrifugal forces that separate liquid from solid. Various blood densities and segments experience different centrifugal effects while flowing through the curved section so serum is separated from various solid matter without using external devices.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
G01N 27/22 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la capacité
Candida antarctica Lipase B (CALB) as a catalyst. The hydrogels are injectable, degradable, and their mechanical and photoluminescent properties are tunable. An in vivo study shows that the hydrogel emits strong fluorescence under visible light excitation and can completely degrade over time.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
C12P 17/14 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'azote ou l'oxygène comme hétéro-atome du cycle et dans le même cycle au moins un autre hétéro-atome différent
Pharmaceutical blends are disclosed herein. In some embodiments, a pharmaceutical blend includes a cohesive active pharmaceutical ingredient (API) and a dry coated pharmaceutical excipient. The dry coated pharmaceutical excipient is present in an amount of about 1 wt % to 99 wt %, based on the total weight of the pharmaceutical blend. The dry coated pharmaceutical excipient includes a core and a shell surrounding the core, wherein the shell partially covers the core of the pharmaceutical excipient.
A61K 9/28 - DragéesPilules ou comprimés avec revêtements
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
